GeneDx Holdings

WGS

Market cap $1.92B

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced it will release financial results for the first quarter of 2026 after the market closes on Monday, May 4, 2026.

Genomics gains momentum as breakthroughs, falling sequencing costs, and CRISPR advances drive precision medicine and fuel rapid market growth.

Robinhood Markets is coming off its weakest top-line growth in two years, and the next few quarters could be worse. GeneDX is the hardest hit stock on this list this year, but it has still bucked the trend by moving higher after a reverse split 35 months ago.

DNUT, GCT, WGS, VSNT and FLOC have been added to the Zacks Rank #1 (Strong Buy) List on April 2nd, 2026.

GENEDX HOLDINGS (WGS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

NWPX, INNV, WGS, BCBP and BWXT have been added to the Zacks Rank #1 (Strong Buy) List on March 18, 2026.

Cathie Wood‘s Ark Invest makes trades across its ETFs every trading day. Those trades are sometimes closely monitored by investors when they involve new stock picks or large trades.

GeneDx Holdings Corp. (WGS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

GAITHERSBURG, Md.--(BUSINESS WIRE)--Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing.

GeneDx launches Zevra-backed testing program to expand ExomeDx access for Niemann-Pick Type C, aiming to speed diagnosis and add data to its Infinity dataset.